# Trophos > Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Trophos > Markdown URL: https://mediated.wiki/source/Trophos.md > Source: https://en.wikipedia.org/wiki/Trophos > Source revision: 1245436979 > License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/) {{Use dmy dates|date=December 2023}} {{Infobox company|name = Trophos|founded = [Marseille](/source/Marseille), France ({{start date|1999}})|fate = Acquired by [Hoffmann-La Roche](/source/Hoffmann-La_Roche)|type = [Privately held company](/source/Privately_held_company)|defunct = {{end date|2015}}|founder = {{unbulleted list|Christopher Henderson|Olivier Pourquie|Jean-Louis Kraus|Antoine Beret|Michel Delaage}}}} '''Trophos''' was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan [neurodegenerative](/source/Neurodegenerative_diseases) diseases and more prevalent disorders.{{Citation needed|date=October 2010}} Trophos was founded in 1999 in [Marseille](/source/Marseille) by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was [olesoxime](/source/olesoxime) (TRO19622),{{cite journal |doi = 10.1124/jpet.107.123000|pmid = 17496168|title = Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis|journal = Journal of Pharmacology and Experimental Therapeutics|volume = 322|issue = 2|pages = 709–720|year = 2007|last1 = Bordet|first1 = T.|last2 = Buisson|first2 = B.|last3 = Michaud|first3 = M.|last4 = Drouot|first4 = C.|last5 = Galea|first5 = P.|last6 = Delaage|first6 = P.|last7 = Akentieva|first7 = N. P.|last8 = Evers|first8 = A. S.|last9 = Covey|first9 = D. F.|last10 = Ostuni|first10 = M. A.|last11 = Lacapere|first11 = J.-J.|last12 = Massaad|first12 = C.|last13 = Schumacher|first13 = M.|last14 = Steidl|first14 = E.-M.|last15 = Maux|first15 = D.|last16 = Delaage|first16 = M.|last17 = Henderson|first17 = C. E.|last18 = Pruss|first18 = R. M.| s2cid=17271734 }}{{Cite web|title = olesoxime|url = http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5002|website = UKMi New Drugs Online Database|accessdate = 2 January 2016}} a mitochondrial targeted compound developed to treat neurodegenerative diseases.{{cite web |url=https://clinicaltrials.gov/ct2/show/NCT00876538 |title=Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy|date=5 February 2010 |publisher=ClinicalTrials.gov |accessdate=3 October 2010}}{{cite web |url=https://clinicaltrials.gov/ct2/show/NCT00868166 |title=Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)|date=May 2010 |publisher=ClinicalTrials.gov |accessdate=3 October 2010}} In January 2015, [Hoffmann-La Roche](/source/Hoffmann-La_Roche) announced its intention to buy Trophos for {{Currency|120 million|EUR}} upfront and up to {{Currency|350 million|EUR}} in milestone performance payments.{{Cite news|url = http://uk.reuters.com/article/us-trophos-m-a-roche-idUKKBN0KP0LO20150116|archive-url = https://web.archive.org/web/20151215051954/http://uk.reuters.com/article/us-trophos-m-a-roche-idUKKBN0KP0LO20150116|url-status = dead|archive-date = 15 December 2015|title = Roche buys France's Trophos to expand in neuromuscular disease|last = Franklin|first = Joshua|date = 16 January 2015|access-date = 30 December 2015|work = Reuters}}{{Cite news|title = Roche to Buy Trophos for Up-to-$543M|last = Staff|date = 15 February 2015|work = [Genetic Engineering & Biotechnology News](/source/Gen._Eng._Biotechnol._News)|type = paper|page = 6|volume = 35|issue = 4}} The deal was completed shortly afterwards. ==References== {{Reflist}} ==Further reading== *{{cite journal |doi=10.1016/j.bcp.2010.04.018|pmid=20417191|title=Olesoxime prevents microtubule-targeting drug neurotoxicity: Selective preservation of EB comets in differentiated neuronal cells|journal=Biochemical Pharmacology|volume=80|issue=6|pages=884–894|year=2010|last1=Rovini|first1=Amandine|last2=Carré|first2=Manon|last3=Bordet|first3=Thierry|last4=Pruss|first4=Rebecca M.|last5=Braguer|first5=Diane}} *{{cite journal |doi=10.1016/j.pain.2009.09.006|pmid=19833436|pmc=2787910|title=Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel|journal=Pain|volume=147|issue=1–3|pages=202–9|year=2009|last1=Xiao|first1=Wen Hua|last2=Zheng|first2=Felix Y.|last3=Bennett|first3=Gary J.|last4=Bordet|first4=Thierry|last5=Pruss|first5=Rebecca M.}} *{{cite journal |doi=10.1124/jpet.108.139410 |pmid=18492948 |title=Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy |journal=Journal of Pharmacology and Experimental Therapeutics |volume=326 |issue=2 |pages=623–632 |year=2008 |last1=Bordet |first1=T. |last2=Buisson |first2=B. |last3=Michaud |first3=M. |last4=Abitbol |first4=J.-L. |last5=Marchand |first5=F. |last6=Grist |first6=J. |last7=Andriambeloson |first7=E. |last8=Malcangio |first8=M. |last9=Pruss |first9=R. M. |s2cid=33726393 }} {{Authority control}} Category:Roche Category:Defunct companies of France Category:French companies established in 1999 Category:Pharmaceutical companies established in 1999 Category:Pharmaceutical companies disestablished in 2015 Category:French companies disestablished in 2015 Category:2015 mergers and acquisitions Category:Companies based in Marseille --- Adapted from the Wikipedia article [Trophos](https://en.wikipedia.org/wiki/Trophos) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Trophos?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.